The assessment made available on the Livbetr website does not create a doctor-patient relationship between the individual completing the assessment and Livbetr. CareValidate Health, a network of US-licensed doctors that adhere to rigorous medical protocols designed for patient safety, has established exclusionary criteria to determine if an individual does not qualify for GLP-1s. The answers an individual provides to the Livbetr assessment determine if the individual is screened out of eligibility for GLP-1 medication, and a CareValidate Health clinician will meet with the individual after checkout to determine if they qualify for a prescription. CareValidate Health clinicians retain the sole discretion to prescribe compounded GLP-1s to patients.

All claims and benefits on this website refer to self-reported data from GLP-1 customers on a treatment plan that includes compounded GLP-1 medications and consultations with medical professionals. Customers reported their weight on their initial medical intake questionnaire and every 3–4 weeks thereafter. Results from compounded medications available through the Livbetr platform may vary and may be affected by an individual's adherence to the program and their clinician's recommendations. Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality. The decision to use compounded drugs is guided by the licensed provider's medical judgment, informed by a telehealth consultation and medical history. We encourage all prospective users of compounded medications to speak with their provider about the specific risks and benefits. Livbetr does not produce compounded medications, and individuals may receive medication that looks different than what is portrayed on the website.

Pharmacy Providers: We are partnered with multiple USA-certified pharmacies to deliver a high-quality product and experience. Our team meets regularly with pharmacy partners to discuss product availability, shipping timelines, and medication testing updates.

Results vary based on starting weight and program adherence. Inches lost may include hips, waist, chest, thighs, and arms in the first month. Patients exercised regularly and followed a reduced-calorie diet. Individual results are not typical and may vary. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. Livbetr patients typically experience 1–2 lbs per week weight loss after 4 weeks, combined with a healthy diet and exercise. Consult a healthcare professional before using any medication or starting a weight loss program. Based on average weight loss reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, alongside reduced calorie intake and increased physical activity.

Medication may be included in the cost of the Livbetr program. Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss. The trademarks, service marks, trade names (Wegovy®, Ozempic®), and products displayed on this site are the property of their respective owners. Medical treatment is provided by "CareGLP Affiliated P.C.s" and CareValidate Health, affiliated networks of medical professional corporations and associations. No data, photos, claims, or other information presented are derived from clinical trials or public studies and are representative of Livbetr patient experience only.